Bladder Cancer Clinical Trial
Evaluation of a Patient-Reported Symptom Index for NMIBC
Summary
This project will develop and evaluate a patient-reported symptom index to assess the impact of treatment for non-muscle invasive bladder cancer on patient burden, toxicity, symptoms and side effects. The symptom index will provide a method for assessing treatments from the patient's perspective; help healthcare professionals make better informed treatment decisions, and provide a method to be able to effectively evaluate treatments for non-muscle invasive bladder cancer.
Full Description
The overarching aim of this research is to develop and evaluate a patient-reported Symptom Index (SI) for individuals with NMIBC (the NMIBC-SI) that is acceptable to patients, reliable, valid and responsive, and fit for purpose in clinical trials and clinical practice.
Specific clinical aims:
Assess and compare key Patient-Reported Outcomes (PROs) across the full range of contemporary treatments for NMIBC, and over the disease trajectory including acute treatment and 1year survivorship;
Compare PROs between patients with low, intermediate, and high risk NMIBC.
In field test 1, 200 participants will complete one questionnaire either in hard copy (pencil and paper) or online, at a time that is convenient for the participant. The questionnaire may take up to 20 minutes to complete.
In field test 2, 250 participants will complete quality of life questionnaires at four different time points; 1) before tumour resection, 2) 1 week after resection, 3) 8 weeks after resection, and 4) 1 year after resection. The questionnaires can be completed in the clinic or at home, either in hard copy (pencil and paper) or online, at a time that is convenient for the participant but still within the relevant time point. The questionnaires may take up to 30 minutes to complete.
Eligibility Criteria
Field test 1:
Inclusion Criteria:
diagnosed NMIBC
Adult (>18yrs)
able to read and understand English
undergoing active treatment (i.e. one week after tumour resection or intravesical therapy) or completed final treatment for NMIBC within the last week
Exclusion Criteria:
unconscious or confused
have cognitive impairment
unable to speak, read and/or write in English
diagnosed with muscle invasive disease
unable to provide informed consent
Field test 2:
Inclusion Criteria:
newly diagnosed NMIBC
Adult (>18yrs)
able to read and understand English
after imaging or flexible cystoscopy, and before active treatment
either before endoscopic resection, or more than 4 weeks since endoscopic resection, but before active/ongoing treatment
Exclusion Criteria:
unconscious or confused
have cognitive impairment
unable to speak, read and/or write in English
diagnosed with muscle invasive disease
unable to provide informed consent
currently undergoing active treatment for any bladder cancer, or finished treatment within last 3 years.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 17 Locations for this study
Kansas City Kansas, 66160, United States
Minneapolis Minnesota, 55455, United States
Rochester Minnesota, 55905, United States
Concord New South Wales, 2139, Australia
St Leonards New South Wales, 2065, Australia
Wagga Wagga New South Wales, 2650, Australia
Westmead New South Wales, 2145, Australia
Westmead New South Wales, 2145, Australia
South Brisbane Queensland, 4101, Australia
Box Hill Victoria, 3128, Australia
Heidelberg Victoria, 3084, Australia
Melbourne Victoria, 3004, Australia
Moorabbin Victoria, 3189, Australia
Parkville Victoria, 3052, Australia
Murdoch Western Australia, 6150, Australia
Vancouver British Columbia, , Canada
Christchurch , 8013, New Zealand
Tauranga , 3140, New Zealand
Salford Manchester, M5 5A, United Kingdom
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.